The Esperion Corstasis acquisition became more than a routine business deal on April 2, 2026. It felt like a turning point in a field where timing can shape a patient’s future. For years, Esperion Therapeutics had built its reputation around lowering cardiovascular risk. But on that morning, as the company announced its purchase of Corstasis Therapeutics, the developer of Enbumyst, the first FDA-approved nasal spray loop diuretic, it marked the moment Esperion stepped into a wider, more urgent mission. The move was not only about expanding a product line. It was about giving patients a quicker and simpler option to manage fluid overload linked to heart failure, kidney disease, and liver disease.
A Therapy Built for Real-World Needs
Enbumyst, based on bumetanide, received its FDA approval in September 2025. It is cleared for adults dealing with edema caused by congestive heart failure, hepatic disease, or renal disease. Its nasal spray delivery introduces an option for people who need rapid relief but cannot rely on oral medications or do not have immediate access to clinical intervention. The treatment offers a way to manage sudden fluid buildup without an IV or hospital visit, which has made it an important addition to outpatient care.
These product details are exactly as presented in Esperion’s disclosures and FDA-aligned information.
Why Esperion Chose Corstasis
Esperion’s main focus has traditionally been therapies aimed at reducing cardiovascular risk, especially cholesterol-related conditions. Corstasis added a new layer of outpatient-ready therapy designed for urgent situations where fluid overload requires fast action. This alignment made the partnership natural and strategic.
The Esperion Corstasis acquisition included $75 million in upfront cash. Additional milestone payments may reach up to $180 million, depending on regulatory and commercial performance. Esperion also secured $50 million in royalty financing tied to its Japan operations to support the deal. All numbers match Esperion’s public announcement.
Bringing Enbumyst Into Everyday Care
Esperion plans to integrate Enbumyst into its existing commercial network, expanding access for clinics, hospitals, and outpatient providers. Its field teams and payer programs will now include a therapy aimed at giving patients faster support in managing swelling and fluid retention.
Industry analysts view the Esperion Corstasis acquisition as a step that widens Esperion’s role in cardiovascular and cardiometabolic care. Enbumyst’s nasal delivery sets it apart from traditional diuretics and fits naturally into real-world patient scenarios.
A Broader Future Ahead
With the acquisition complete, Esperion moves into a more expansive role in cardiovascular care. By adding a unique, FDA-approved therapy to its portfolio, the company strengthens its ability to support patients across the US healthcare system.
